- Home
- MGEE vs SUPN Comparison
MGEE vs SUPN Comparison
Compare MGEE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | SUPN |
|---|---|---|
| Founded | 1855 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2001 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MGEE | SUPN |
|---|---|---|
| Price | $77.23 | $54.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $78.00 | $61.60 |
| AVG Volume (30 Days) | 90.1K | ★ 750.5K |
| Earning Date | 05-25-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $4.02 | $23.19 |
| Revenue Next Year | $2.77 | $17.65 |
| P/E Ratio | $21.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.47 | $29.16 |
| 52 Week High | $94.78 | $59.68 |
Technical Indicators
Market Signals| Indicator | MGEE | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 58.80 |
| Support Level | N/A | $47.95 |
| Resistance Level | $82.75 | $58.67 |
| Average True Range (ATR) | 1.68 | 2.35 |
| MACD | -0.50 | 0.02 |
| Stochastic Oscillator | 10.14 | 50.60 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.